Ensayo clínico NCT06561386 · Non-small Cell Lung Cancer

Ensayo clínico NCT06561386 (fase III) figura como «en reclutamiento» en ClinicalTrials.gov.

Patología: Non-small Cell Lung Cancer · Intervenciones registradas: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin · Fechas registradas (fuente): 2024-10-07, 2030-07-30, 2024-08-20, 2026-10-23.

Resumen del estudio (fuente: ClinicalTrials.gov, texto original en inglés):

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Fuente: https://clinicaltrials.gov/study/NCT06561386